jRCT2031230029已完成不适用
RGB-19 Phase I Clinical Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 110
- 主要终点
- Maximum serum drug concentration
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Crossover Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 40age old under（—）
- 性别
- Male
入选标准
- •Male volunteers who voluntarily wish to participate in the study, have the capacity to provide consent, and have provided written informed consent to participate in the study.
- •Volunteers from 20 to 40 years of age (both inclusive) when signing informed consent.
排除标准
- •Volunteers previously exposed to tocilizumab, any other IL-6 inhibitors, or IL-6 receptor inhibitors.
结局指标
主要结局
Maximum serum drug concentration
Cmax
AUC from 0 hours to infinity
AUCinf
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
RGB-19 Phase I Clinical StudyHealthy ParticipantsJPRN-jRCT2031230029Watanabe Manabu110
招募中
3 期
RGB-19 Phase III Clinical StudyActive Rheumatoid ArthritisJPRN-jRCT2031220512Watanabe Manabu358
招募中
1 期
Phase I and IIa clinical studies of PBR-001 targeting patients with myopic chorioretinal atrophyJPRN-jRCT2043200105Kusano HItoshi10
已完成
不适用
Technical Note and Initial Clinical, Prospective Results After LUCL / MCL Refixation with Additive FiberTape Augmentation (Internal Bracing) for Elbow InstabilityS53Diseases of the ligaments : Upper arm [humerus, elbow joint].M24.22Dislocation, sprain and strain of joints and ligaments of elbowDRKS00012813Medizinische Hochschule Hannover34
招募中
2 期
Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion of TL-895 Monotherapy and Combination Therapy with Navtemadlin in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Subjects and Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia or Relapsed/Refractory Small Lymphocytic Lymphoma2024-516691-14-00Telios Pharma Inc.69